Latest News

Ali A. Habib, MD  (Credit: UCI School of Medicine)
Phase 3b ADAPT NXT Study Confirms Efficacy of Cyclic and Biweekly Dosing of Efgartigimod in Generalized Myasthenia Gravis

October 17th 2024

Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis.

Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis
Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis

October 17th 2024

Greg Divis  (Credit: Avadel Pharmaceuticals)
FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy

October 17th 2024

Robert A. Hauser, MD, MBA  (Credit: USF Health)
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment

October 17th 2024

Tuan Vu, MD  (Credit: LinkedIn)
Rozanolixizumab Efficacious in Older Patients With Generalized Myasthenia Gravis, Phase 3 Data Show

October 17th 2024

Coverage of the American Association of Neuromuscular & Electrodiagnostic Medicine 2024 Meeting

Get expert-driven insight and coverage of key data and research straight from the conference floor in Savannah.

AANEM 2024

Conference Coverage

View All
Ali A. Habib, MD  (Credit: UCI School of Medicine)
Phase 3b ADAPT NXT Study Confirms Efficacy of Cyclic and Biweekly Dosing of Efgartigimod in Generalized Myasthenia Gravis

October 17th 2024

Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis
Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis

October 17th 2024

Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD
Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

October 17th 2024

Tuan Vu, MD  (Credit: LinkedIn)
Rozanolixizumab Efficacious in Older Patients With Generalized Myasthenia Gravis, Phase 3 Data Show

October 17th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.